KRAS and cancer: One trial assesses the safety and efficacy of ELI-002 immunotherapy, a novel amphiphile therapeutic vaccine targeting KRAS-driven cancers, for patients with KRAS or NRAS mutations (G12D or G12R) in various solid tumor types including GBC (NCT04853017).